Nanotechnology Now - Press Release: Lumera’s ProteomicProcessor™ Enables Researchers to Find Novel Biomarkers in Liver Serum

Home > Press > Lumera’s ProteomicProcessor™ Enables Researchers to Find Novel Biomarkers in Liver Serum

Abstract:
Researchers from the Institute for Systems Biology Present Liver Toxicology Data at HUPO.

Lumera’s ProteomicProcessor™ Enables Researchers to Find Novel Biomarkers in Liver Serum

BOTHELL, WA | Posted on March 8th, 2007

Lumera Corporation (NASDAQ:LMRA), a leader in the emerging field of nanotechnology, announced today that collaborators at The Institute for Systems Biology (ISB) have used Lumera's ProteomicProcessor™ beta instrument to identify a novel biomarker panel associated with liver toxicity in mice.

The findings, presented this week at the US Human Proteome Organization (HUPO) meeting in Seattle, WA, demonstrated the measurement of liver-specific proteins in the serum during early toxic effects, maximal toxic effects, and the recovery stages of liver injury caused by acetaminophen overdose. Toxicant- and drug-induced liver injury (DILI) is an increasingly serious health problem and, while a single biomarker is unlikely to indicate DILI accurately, characteristic signatures with a panel of biomarkers are envisioned to be more informative for distinguishing different injuries.

Using a microarray with a panel of specific antibodies, the ISB researchers used Lumera's ProteomicProcessor™ to look at changes in protein expression. The ProteomicProcessor™ provides the unique ability to look at up to 5,000 distinct interactions without the need for a fluorescent label.

"ISB's demonstration of how our platform can be used in biomarker discovery is quite exciting and could have broad implications in the biomarker space. We feel extremely fortunate to have Leroy Hood's team focused on this critically important path," said Dr. Tim Londergan, Bioscience Business Unit Director at Lumera.

According to a recent industry report (source: Kalorama's "Biomarkers: A Market Briefing"), new biomarkers have reduced the time and cost in Phase I and II clinical trials and are currently producing an estimated $200 million in revenue. This number is expected to quintuple in the next four years.

####

About Lumera
Lumera is a leader in the emerging field of nanotechnology. The company designs proprietary molecular structures and polymer compounds for the bioscience and communications/computing industries, both of which represent large market opportunities. The company also has developed proprietary processes for fabricating such devices.

About the Institute for Systems Biology

The Institute for Systems Biology (ISB) is an internationally renowned, non-profit research institute headquartered in Seattle and dedicated to the study and application of systems biology. Founded by Leroy Hood, Alan Aderem and Ruedi Aebersold, ISB seeks to unravel the mysteries of human biology and identify strategies for predicting and preventing diseases such as cancer, diabetes and AIDS. ISB’s systems approach integrates biology, computation and technological development, enabling scientists to analyze all elements in a biological system rather than one gene or protein at a time. Founded in 2000, the Institute has grown to 12 faculty and more than 180 staff members; an annual budget of more than $25 million; and an extensive network of academic and industrial partners. For more information about ISB, visit http://www.systemsbiology.org

Certain statements contained in this release are forward-looking statements that involve a number of risks and uncertainties. Factors that could cause actual results to differ materially from those projected in the company's forward-looking statements include the following: market acceptance of our technologies and products; our ability to obtain financing; our financial and technical resources relative to those of our competitors; our ability to keep up with rapid technological change; government regulation of our technologies; our ability to enforce our intellectual property rights and protect our proprietary technologies; the ability to obtain additional contract awards and to develop partnership opportunities; the timing of commercial product launches; the ability to achieve key technical milestones in key products; and other risk factors identified from time to time in the company's SEC reports, including in its registrations statement on Form S-1, dated July 22, 2004 and its Quarterly Reports on Form 10-Q.

For more information, please click here

Contacts:
The Summit Group Communications
Todd Wolfenbarger
801-595-1155
801-244-9600 cell

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: